United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

Posted by Linda Flegge on Apr 21st, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $577.86, for a total transaction of $5,778,600.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,907,685.36. This trade represents a 34.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

James Edgemond also recently made the following trade(s):

On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.18, for a total transaction of $5,771,800.00.
On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.88, for a total value of $5,748,800.00.
On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.89, for a total value of $5,778,900.00.
On Monday, April 6th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $558.40, for a total value of $5,584,000.00.
On Thursday, April 2nd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $561.50, for a total value of $5,615,000.00.
On Monday, March 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $593.17, for a total value of $5,931,700.00.
On Thursday, March 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $535.90, for a total transaction of $5,359,000.00.
On Monday, March 23rd, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $573.44 on Tuesday. The business’s 50-day moving average is $528.74 and its 200-day moving average is $491.26. The company has a market capitalization of $25.13 billion, a price-to-earnings ratio of 20.55, a P/E/G ratio of 1.68 and a beta of 0.75. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $607.89.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period last year, the company earned $6.19 earnings per share. Analysts anticipate that United Therapeutics Corporation will post 27.93 EPS for the current year.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

Positive Sentiment: Company will present multiple new data sets at ISHLT (ARTISAN and PHINDER interim analyses) showing potential earlier detection/management of pulmonary hypertension and cardiac improvement with high‑dose treprostinil—supports pipeline and commercial outlook. Read More.
Positive Sentiment: Potential regulatory catalyst: commentary that the “bull case” could change if FDA grants RMAT for miroliverELAP — a favorable RMAT would materially re‑rate pipeline value. Read More.
Positive Sentiment: Analyst coverage remains constructive with several price‑target increases and a consensus “Moderate Buy,” providing valuation support amid volatility. Read More.
Neutral Sentiment: Institutional moves: Asset Management One slightly trimmed its stake (small share reduction) — not large enough alone to drive trend. Read More.
Neutral Sentiment: Valuation pieces and unusually large options activity are drawing attention from traders and value investors; these items can amplify intraday moves but are directionally ambiguous. Read More. Read More.
Negative Sentiment: Significant insider selling: CEO Martine Rothblatt sold 9,500 shares (multiple filings) and CFO James Edgemond sold 10,000 shares this week — large, closely timed sales by senior executives often create near‑term selling pressure or signal personal liquidity choices. Read More. Read More.
Negative Sentiment: Additional director sale reported — the cluster of senior‑level disposals in close succession increases perceived near‑term risk even though insiders still hold meaningful stakes. Read More.

Analyst Ratings Changes

Several equities analysts recently issued reports on UTHR shares. Cantor Fitzgerald upped their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Raymond James Financial began coverage on shares of United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price on the stock. Bank of America boosted their price objective on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Wells Fargo & Company upped their target price on shares of United Therapeutics from $486.00 to $575.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 31st. Finally, TD Cowen raised their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research note on Monday, March 30th. Ten investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $601.50.

Read Our Latest Research Report on UTHR

Hedge Funds Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Clearstead Advisors LLC raised its stake in United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 23 shares in the last quarter. Independent Advisor Alliance raised its position in United Therapeutics by 3.3% in the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after buying an additional 27 shares during the last quarter. Bessemer Group Inc. grew its stake in shares of United Therapeutics by 2.6% during the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after acquiring an additional 28 shares during the period. Florida Financial Advisors LLC boosted its stake in United Therapeutics by 5.4% in the 4th quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after purchasing an additional 28 shares during the period. Finally, NDVR Inc. raised its holdings in shares of United Therapeutics by 5.1% in the 4th quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 30 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.